We should have better protection than the Northern Hemisphere had
Each winter, New Zealand faces the quiet arithmetic of influenza — around 500 lives lost, hospitals strained, and communities reminded that a preventable illness still carries real weight. This year, a faster-spreading variant of H3N2 known as 'Super-K' has already overwhelmed hospitals in the United Kingdom, and it is now circulating in the Southern Hemisphere. Yet there is a meaningful counterweight: New Zealand's vaccines have been specifically formulated to address this strain, offering a degree of protection that Northern Hemisphere populations did not have. The season ahead will test not only the virus's reach, but society's willingness to act before the peak arrives.
- The Super-K strain spreads faster than typical seasonal flu and drove record UK hospital admissions last December, raising alarm as New Zealand's winter begins.
- Vaccination rates remain dangerously low — only 60% of eligible over-65s and just 5% of qualifying young children received flu shots last year, leaving the most vulnerable exposed.
- Unlike Northern Hemisphere counterparts, New Zealanders have access to vaccines specifically formulated against Super-K, giving vaccinated individuals roughly 69% lower risk of infection.
- Health authorities are pushing toward 75% coverage among older adults and calling for expanded free access to all children under five and enhanced vaccines for those over 75.
- The window to act is open now — vaccination is available through GPs, pharmacies, and online booking — but the season typically peaks between May and October, and time is narrowing.
The cold months are arriving in New Zealand, and with them a strain of influenza that has already tested the Northern Hemisphere. The H3N2 Subclade K — 'Super-K' — spread earlier and faster than typical seasonal flu, filling UK hospitals with record admissions last December. Health authorities are bracing for a potentially severe season, though they hold one significant advantage: this winter's vaccines have been specifically formulated to counter Super-K more effectively than those available in Europe and North America.
The funded vaccine, Influvac Tetra, is free for people over 65, pregnant people, those with chronic conditions, and children under five with significant respiratory histories. For everyone else, it costs $25–$40 at most pharmacies. Three additional options exist at higher cost, including Fluad — an enhanced vaccine particularly beneficial for those over 75 — which is free for older Australians but not yet funded here.
The deeper challenge is uptake. Last year, only 60% of eligible older adults and a mere 5% of qualifying young children were vaccinated. Health authorities estimate roughly 500 New Zealanders die from influenza annually, yet coverage remains below what experts consider adequate. Dr. Joan Ingram of the University of Auckland has called for free vaccination to be extended to all children under five and for enhanced vaccines to be funded for older adults — changes experts say would reduce not only individual illness but hospitalisations and community transmission alike.
Super-K is not a new virus, but a mutated form of H3N2 with altered proteins that allow it to spread more readily. It arrived in New Zealand and Australia earlier than expected, in October and November of last year. It has not been shown to cause more severe disease, but its speed is notable — and vaccinated New Zealanders are better placed than most to meet it.
Flu patterns have grown less predictable since the COVID-19 pandemic disrupted normal seasonal cycles, with peaks now shifting unpredictably rather than following the traditional winter arc. Experts urge vaccination early in the season, particularly for those over 65. Booking is straightforward — by phone, online, at a GP, or at most pharmacies — and the immunisation programme runs through December. More than one million doses are administered in New Zealand each year; the goal now is to reach more of those who need it most, before the season takes hold.
The cold months are arriving, and with them comes the familiar sound of coughing spreading through offices and homes. New Zealand's flu season is underway, and this year carries an unusual threat: a strain of influenza that has already disrupted the Northern Hemisphere and is now circulating locally. The H3N2 Subclade K—known colloquially as "super-k"—spread earlier and faster than typical seasonal flu, overwhelming hospitals in the UK with record admissions last December. Health authorities here are bracing for a potentially severe season, though they have one advantage: the vaccines being rolled out this winter have been specifically formulated to counter this variant more effectively than those available to people in Europe and North America.
Influenza mutates constantly, which is why the vaccine changes every year. This year's funded option is Influvac Tetra, available free to people over 65, pregnant people, those with chronic conditions like diabetes or asthma, and children under five with significant respiratory histories. For everyone else, the vaccine typically costs between $25 and $40 at pharmacies. Three additional vaccines are available at higher cost: Flucelvax, a cell-based alternative that has shown 8 percent greater effectiveness than egg-based vaccines over multiple seasons; Fluzone, which is similar to Influvac; and Fluad, an adjuvanted vaccine that appears particularly beneficial for people over 75 but costs around $50 and is not funded in New Zealand, despite being free for over-65s in Australia.
The challenge facing public health officials is not primarily the virus itself, but persuading people to get vaccinated. Last year, only 60 percent of eligible people over 65 received a flu shot, and just 5 percent of children under five who qualified for free vaccination actually got one. Cost is a barrier, but it is not the only one. Health authorities estimate that roughly 500 New Zealanders die from influenza each year, yet vaccination rates remain below what experts consider adequate. This year's goal is to reach 75 percent coverage among people over 65. Dr. Joan Ingram, medical advisor for the Immunisation Advisory Centre at the University of Auckland, notes that vaccination remains the most effective way to prevent hospitalisations and severe outcomes, and she has called for the vaccine to be funded for all children under five and for older adults to have access to enhanced vaccines at no cost.
The super-k strain itself is not a new virus, but rather a mutated version of H3N2 that has altered one of its key proteins, allowing it to spread more readily. It arrived in New Zealand and Australia earlier than expected, in October and November of last year, contributing to unusual flu activity outside the typical winter peak. The strain has not been shown to cause more severe disease than other flu variants, but its transmission speed has been remarkable. Yet New Zealand has a distinct advantage: the vaccines available here include a strain component specifically chosen to provide protection against super-k, something the Northern Hemisphere vaccines did not include. This means vaccinated New Zealanders should have better protection than their counterparts in Europe and North America faced.
Booking a vaccination is straightforward. People can call 0800 28 29 26 between 8:30 a.m. and 5 p.m. on weekdays, use the Book My Vaccine online system, visit their GP, or go to most pharmacies. The immunisation programme runs from April through December, with the flu season typically peaking between May and October, though recent years have seen peaks shift to late August. After receiving the vaccine, patients are asked to wait 15 minutes to ensure no adverse reactions occur. Serious allergic reactions are rare. Mild side effects like slight fever or soreness at the injection site are common and temporary. The vaccine does not contain live virus and cannot cause influenza, though it does not guarantee immunity—rather, it substantially reduces the risk of infection and serious illness. In 2025, vaccinated people had approximately 69 percent lower risk of infection than the unvaccinated.
Health experts have noted that flu patterns have become less predictable since the COVID-19 pandemic disrupted normal seasonal respiratory virus cycles. Peter McIntyre, head of the Department of Paediatrics and Child Health at the University of Otago, points out that influenza now arrives at unpredictable times rather than following the traditional winter peak. This unpredictability, combined with the arrival of super-k, underscores why vaccination early in the season matters. For those over 65, particularly those over 75, getting vaccinated now is strongly recommended. Ingram also suggests that when getting a flu vaccine, people should consider updating their COVID-19 vaccination if they are older or have health conditions that increase their risk of severe COVID-19.
The broader question facing New Zealand's health system is whether current funding levels for flu vaccination are adequate. Experts argue that expanding free access to all young children and providing funded enhanced vaccines for older adults would improve uptake and reduce not only individual illness but also hospitalisations, antibiotic use, and transmission within families and communities. For now, the campaign is underway, and the window to protect oneself before the season peaks is open. More than one million flu vaccines are administered in New Zealand each year, yet the goal remains to reach more people, particularly those at highest risk, before super-k and other circulating strains take hold.
Citações Notáveis
Vaccination is the most effective means to reduce hospitalisations and severe outcomes from influenza.— Dr. Joan Ingram, Immunisation Advisory Centre
One of the strains in each vaccine is expected to provide protection against the K variant and was not included in the northern hemisphere vaccines—so we should have better protection.— Dr. Joan Ingram
A Conversa do Hearth Outra perspectiva sobre a história
Why does New Zealand have better vaccines for super-k than the Northern Hemisphere did?
The vaccine formulation is chosen months in advance, based on predictions about which strains will circulate. The Northern Hemisphere made their choice before super-k became the dominant concern. New Zealand's vaccine includes a strain component specifically selected to address super-k, which gives us a real advantage.
So the virus isn't actually more dangerous—it just spreads faster?
Exactly. Super-k mutated in a way that makes it transmit more readily, which is why it overwhelmed UK hospitals. But the disease itself isn't necessarily worse. The danger is volume and speed, not severity.
Why are only 60 percent of eligible elderly people getting vaccinated if it's free?
That's the puzzle. Cost isn't the only barrier. Some people are hesitant about vaccines generally, some forget, some don't think they need it. But the real frustration for health authorities is that we know vaccination works—it cuts infection risk by about 69 percent—yet uptake remains stubbornly low.
What's the argument for funding Fluad for everyone over 65?
Fluad has an adjuvant that triggers a stronger immune response, and the evidence shows it's particularly beneficial for people over 75 and those with multiple health conditions. Australia funds it for over-65s. Here, you have to pay around $50. Experts think that's a missed opportunity, especially given how many elderly people die from flu each year.
Is there anything on the horizon that might change how people get vaccinated?
Nasal spray vaccines are in development and may arrive here eventually. That would remove the needle barrier, which might help with uptake, especially in children. But for now, you still have to grit your teeth and take the jab.